IMATINIB-TEVA imatinib 400 mg film-coated tablets blister pack

국가: 오스트레일리아

언어: 영어

출처: Department of Health (Therapeutic Goods Administration)

유효 성분:

imatinib mesilate, Quantity: 477.877 mg (Equivalent: imatinib, Qty 400 mg)

제공처:

Teva Pharma Australia Pty Ltd

INN (International Name):

imatinib mesilate

약제 형태:

Tablet, film coated

구성:

Excipient Ingredients: calcium hydrogen phosphate; crospovidone; magnesium stearate; purified water; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; macrogol 4000; polyvinyl alcohol

관리 경로:

Oral

패키지 단위:

90 film-coated tablets, 30 film-coated tablets

처방전 유형:

(S4) Prescription Only Medicine

치료 징후:

1) IMATINIB-TEVA (imatinib) is indicated for the treatment of patients with chronic myeloid leukaemia (CML). 2) IMATINIB-TEVA (imatinib) is indicated for the treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. 3) IMATINIB-TEVA (imatinib) is indicated for the treatment of adult patients with relapsed or refractory Ph+ALL as monotherapy. 4) IMATINIB-TEVA (imatinib) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene rearrangements, where conventional therapies have failed. 5) IMATINIB-TEVA (imatinib) is indicated for the treatment of adult patients with aggressive systemic mastocytosis (ASM), where conventional therapies have failed. 6) IMATINIB-TEVA (imatinib) is indicated for the treatment of adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL). 7) IMATINIB-TEVA (imatinib) is indicated for the Treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST) 8) IMATINIB-TEVA (imatinib) is indicated for the adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of KIT (CD117)-positive primary GIST. 9) IMATINIB-TEVA (imatinib) is indicated for the treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).

제품 요약:

Visual Identification: Imatinib tablets 400 mg are dark yellow to brownish oblong film coated tablets debossed with IT and 4 divided by score line on one side.; Container Type: Blister Pack; Container Material: PVC/PE/PVDC/Al; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

승인 상태:

Licence status A

승인 날짜:

2016-06-10

환자 정보 전단

IMATINIB-TEVA
®
_Imatinib (as mesilate) film-coated tablets_
CONSUMER MEDICINE INFORMATION
WHAT IS IN THIS LEAFLET
This leaflet answers some common
questions about imatinib.
The information in this leaflet was
last updated on the date listed on the
final page. More recent information
on the medicine may be available.
YOU SHOULD ENSURE THAT YOU SPEAK
TO YOUR PHARMACIST OR DOCTOR TO
OBTAIN THE MOST UP TO DATE
INFORMATION ON THE MEDICINE. YOU
CAN ALSO DOWNLOAD THE MOST UP TO
DATE LEAFLET FROM WWW.TEVA.COM.AU.
Those updates may contain important
information about the medicine and
its use of which you should be aware.
It does not contain all the available
information. It does not take the
place of talking to your doctor or
pharmacist.
All medicines have risks and
benefits. Your doctor has weighed
the risks of you taking this medicine
against the benefits they expect it
will provide.
IF YOU HAVE ANY CONCERNS ABOUT THIS
MEDICINE, ASK YOUR DOCTOR OR
PHARMACIST.
KEEP THIS LEAFLET WITH THE MEDICINE.
You may need to read it again.
WHAT IMATINIB IS USED
FOR
Imatinib is used to treat adults and
children/adolescents who have
chronic myeloid leukaemia (CML)
and acute lymphoblastic leukaemia
with Philadelphia chromosome
positive (Ph-positive ALL).
CML and ALL are types of
leukaemia in which an abnormal
chromosome produces an enzyme
that leads to uncontrolled growth of
white blood cells. Imatinib kills the
abnormal cells while leaving normal
cells alone.
Imatinib is also used to treat adults
for:
•
myelodysplastic /
myeloproliferative diseases
(MDS/MPD).
These are a group of blood
diseases in which some blood
cells start growing out of control.
•
Aggressive systemic mastocytosis
(ASM).
It is a cancer in which certain
blood cells, called "mast" cells,
grow out of control.
•
Hypereosinophilic syndrome
(HES) and or chronic
eosinophilic leukaemia (CEL).
These are blood diseases in which
some blood cells, named
"eosinophils", start growing out
of control.
•
gastro-intestinal stromal tumours
(GIST).
This is a type of cancer of

제품 특성 요약

Teva Pharma Australia Pty Limited Version 7 1
AUSTRALIAN PI – IMATINIB-TEVA
® (IMATINIB (AS MESILATE)) FILM
COATED TABLETS
1
NAME OF THE MEDICINE
The active ingredient is Imatinib (as mesilate).
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
IMATINIB-TEVA tablets contain either 100 mg or 400 mg of imatinib (as
mesilate) as the active
ingredient.
For the full list of excipients, see Section 6.1 List of excipients.
3
PHARMACEUTICAL FORM
IMATINIB-TEVA 100 mg
film-coated tablet:
contains 100mg of imatinib equivalent to 119.5mg imatinib (as
mesilate)
in a dark yellow to brownish orange round film coated tablet debossed
with IT and 1 divided by score line on one side.
IMATINIB-TEVA 400 mg
film-coated tablet:
contains 400mg of imatinib equivalent to 477.9mg imatinib (as
mesilate)
in a dark yellow to brownish orange oblong film coated tablet debossed
with IT and 4 divided by score line on one side.
4
CLINICAL PARTICULARS
4.1
T
HERAPEUTIC INDICATIONS
Imatinib-Teva is indicated for the:
•
treatment of patients with chronic myeloid leukaemia (CML)
•
treatment of adult and paediatric patients with newly diagnosed
Philadelphia chromosome
positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with
chemotherapy
•
treatment of adult patients with relapsed or refractory Ph+ ALL as
monotherapy
•
treatment of adult patients with myelodysplastic/myeloproliferative
diseases (MDS/MPD)
associated with platelet-derived growth factor receptor (PDGFR) gene
re-arrangements, where
conventional therapies have failed
•
treatment of adult patients with aggressive systemic mastocytosis
(ASM), where conventional
therapies have failed
•
treatment of adult patients with hypereosinophilic syndrome (HES)
and/or chronic eosinophilic
leukaemia (CEL)
•
treatment of patients with KIT (CD117) positive unresectable and/or
metastatic malignant
gastrointestinal stromal tumours (GIST)
•
adjuvant treatment of adult patients at high risk of recurrence
following complete gross
resection of KIT (CD117)-positive primary GIST (see Dosage and
Ad